A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Evinacumab in Healthy Japanese and Caucasian Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 15 Feb 2018 Planned End Date changed from 13 Jun 2018 to 31 Jul 2018.
- 15 Feb 2018 Planned primary completion date changed from 13 Jun 2018 to 31 Jul 2018.
- 15 Feb 2018 Status changed from recruiting to active, no longer recruiting.